KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Investing Activities (2016 - 2025)

Boston Scientific (BSX) has disclosed Cash from Investing Activities for 17 consecutive years, with -$512.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 86.18% to -$512.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 billion through Dec 2025, up 53.58% year-over-year, with the annual reading at -$2.6 billion for FY2025, 53.58% up from the prior year.
  • Cash from Investing Activities hit -$512.0 million in Q4 2025 for Boston Scientific, down from -$502.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $71.0 million in Q1 2021 to a low of -$3.7 billion in Q4 2024.
  • Historically, Cash from Investing Activities has averaged -$763.6 million across 5 years, with a median of -$500.0 million in 2025.
  • Biggest five-year swings in Cash from Investing Activities: soared 193.42% in 2021 and later tumbled 2796.55% in 2023.
  • Year by year, Cash from Investing Activities stood at -$461.0 million in 2021, then skyrocketed by 60.3% to -$183.0 million in 2022, then tumbled by 475.41% to -$1.1 billion in 2023, then tumbled by 251.76% to -$3.7 billion in 2024, then surged by 86.18% to -$512.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for BSX at -$512.0 million in Q4 2025, -$502.0 million in Q3 2025, and -$1.1 billion in Q2 2025.